EXAS - Earnings announcements

Fourth quarter and 2025 highlights Total fourth quarter revenue of $878 million, an increase of 23% on a reported and core revenue basis, with Screening revenue of $695 million and Precision Oncology revenue of $183 million Total 2025 revenue of $3.25 billion, an increase of 18% on a reported and core revenue basis, with Screening revenue of $2.53 billion and Precision Oncology revenue of $717 million Operating cash flow was $491 million and free cash flow was $357 million for the full-year 2025, an improvement of 133% and 379%, respectively Net loss was $208 million and adjusted EBITDA was $400 million for the full-year 2025, an improvement of $821 million and $77 million, resp

Acquisition adds a new growth vertical to Abbott's already high single-digit growth profile, gaining leadership in the fast-growing $60 billion U.S. cancer screening and precision oncology diagnostics segmentsAcquisition will uniquely position Abbott to transform cancer care, advancing earlier detection and optimizing treatment and monitoring to help millions more people live healthier livesExact Sciences' product lines feature advanced cancer screening and diagnostic solutions, including the market-leading Cologuard® and Oncotype DX® tests, and cutting-edge liquid biopsy tests for multi-cancer early detection and molecular residual disease testingAcquisition will be immediately accretive to

Reports record revenue, raises full-year guidance, generates record cash from operations Third quarter and recent highlights Delivered record total third quarter revenue of $851 million, an increase of 20% on a reported and core revenue basis, including Screening revenue of $666 million and Precision Oncology revenue of $184 million Raised full-year 2025 revenue and adjusted EBITDA guidance midpoints by $78 million and $10 million, respectively Generated record cash from operations and free cash flow Launched Cancerguard®, the company's multi-cancer early detection test, for patients in the United States Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer scree

Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third quarter 2025 financial results after the close of the U.S. financial markets on November 3, 2025. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. Third quarter 2025 webcast & conference call details Date: Monday, November 3, 2025 Time: 5 p.m. ET Webcast: The live webcast can be accessed at www.exactsciences.com Telephone: Domestic callers, dial 888-330-2384 International callers

Reports record revenue, improves adjusted EBITDA, raises full-year guidance Second quarter and recent highlights Delivered record total second quarter revenue of $811 million, an increase of 16% on a reported and core revenue basis, including Screening revenue of $628 million and Precision Oncology revenue of $183 million Raised full-year 2025 revenue and adjusted EBITDA guidance midpoints by $55 million and $25 million, respectively Entered into an exclusive license agreement with Freenome for blood-based colorectal cancer screening tests Gained Medicare coverage for Oncodetect™ molecular residual disease and recurrence monitoring test Announced a multi-year productivity p

Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2025 financial results after the close of the U.S. financial markets on August 6, 2025. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. Second quarter 2025 webcast & conference call details Date: Wednesday, August 6, 2025 Time: 5 p.m. ET Webcast: The live webcast can be accessed at www.exactsciences.com Telephone: Domestic callers, dial 888-330-2384 International callers, d

First quarter highlights Delivered total first quarter revenue of $707 million, an increase of 11% on a reported and core revenue basis, including Screening revenue of $540 million and Precision Oncology revenue of $167 million Raised full-year 2025 revenue and adjusted EBITDA guidance midpoints by $40 million and $15 million, respectively Launched the Cologuard Plus™ test, the company's next-generation colon cancer screening test Presented data in the Journal of Surgical Oncology demonstrating the clinical strength of the Oncodetect™ test, the company's molecular residual disease ("MRD") and recurrence monitoring test Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of canc

Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 2025 financial results after the close of the U.S. financial markets on May 1, 2025. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. First quarter 2025 webcast & conference call details Date: Thursday, May 1, 2025 Time: 5 p.m. ET Webcast: The live webcast can be accessed at www.exactsciences.com Telephone: Domestic callers, dial 888-330-2384 International callers, dial +1 240-789-2701 Access cod

Fourth quarter and 2024 highlights Total fourth quarter revenue of $713 million, an increase of 10%, or 11% on a core revenue basis, with Screening revenue of $553 million and Precision Oncology revenue of $161 million Total 2024 revenue of $2.76 billion, an increase of 10%, or 11% on a core revenue basis, with Screening revenue of $2.10 billion and Precision Oncology revenue of $655 million Plans to launch three new cancer tests in 2025: Cologuard Plus™, next-generation colorectal cancer screening test, Oncodetect™, molecular residual disease test, and Cancerguard™, multi-cancer screening test Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic

Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its fourth quarter 2024 financial results after the close of the U.S. financial markets on February 19, 2025. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. Fourth quarter 2024 webcast & conference call details Date:    Wednesday, February 19, 2025 Time:    5 p.m. ET Webcast:    The live webcast can be accessed at www.exactsciences.com Telephone:    Domestic callers

Delivered record revenue and cash flow, improved adjusted EBITDA, advanced pipeline Third quarter highlights Total third quarter revenue of $709 million, an increase of 13% on a reported and core revenue basis, including Screening revenue of $545 million and Precision Oncology revenue of $164 million Net loss was $38 million, adjusted EBITDA was $99 million, and adjusted EBITDA margin increased 500 basis points to 14% Operating cash flow was $139 million with free cash flow of $113 million Received FDA approval for the Cologuard Plus™ test, the Company's next-generation Cologuard® test Presented data showing potential of its blood-based colorectal cancer screening test, with sens

Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third quarter 2024 financial results after the close of the U.S. financial markets on November 5, 2024. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. Third quarter 2024 webcast & conference call details           Date:   Tuesday, November 5, 2024    Time:   5 p.m. ET    Webcast:   The live webcast can be accessed at www.exactsciences.com    Telephone:   Domestic callers, dial 888-330-2384      Inte

Reports record results, screened more than 1 million people with Cologuard®, raises adjusted EBITDA guidance Second quarter highlights Delivered total second quarter revenue of $699 million, an increase of 12%, or 13% on a core revenue basis, including Screening revenue of $532 million and Precision Oncology revenue of $168 million Screened more than 1 million people with Cologuard for the first time during a quarter and tested a record number of cancer patients with Oncotype DX® Advanced pipeline by generating evidence supporting molecular residual disease, multi-cancer screening, and blood-based colorectal cancer screening tests Maintains full-year 2024 revenue guidance and

Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2024 financial results after the close of the U.S. financial markets on July 31, 2024. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. Second quarter 2024 webcast & conference call details Date: Wednesday, July 31, 2024 Time: 5 p.m. ET Webcast: The live webcast can be accessed at www.exactsciences.com Telephone: Domestic callers, dial 888-330-2384 International callers, dial +1 240-789

First quarter highlights Delivered total first quarter revenue of $638 million, an increase of 6% on a reported and core revenue basis, including Screening revenue of $475 million and Precision Oncology revenue of $163 million Published Cologuard Plus™ test results from pivotal BLUE-C study in The New England Journal of Medicine Maintains full-year 2024 revenue and adjusted EBITDA guidance Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $638 million for the first quarter ended March 31, 2024, compared to $602 million for the same period of 2023. "The Exact Sciences team is of

Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 2024 financial results after the close of the U.S. financial markets on May 8, 2024. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. First quarter 2024 webcast & conference call details Date:   Wednesday, May 8, 2024 Time:   5 p.m. ET Webcast:   The live webcast can be accessed at www.exactsciences.com Telephone:   Domestic callers, dial 888-330-2384

Cologuard Plus is only noninvasive test to be evaluated head-to-head against an independent fecal immunochemical test, which it significantly outperformed 20,000-participant BLUE-C study included 98 colorectal cancers and reflects racial and ethnic diversity of U.S. Company will host conference call and webcast at 8:00 a.m. ET on March 14 to discuss study results Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced online publication of the BLUE-C study results in The New England Journal of Medicine. The peer-reviewed study, "Next-Generation Multitarget Stool DNA Test for Colorectal Cancer Screening", will also appear in the

Reports record revenue, generates positive free cash flow, expects 2024 revenue of $2.810-2.850 billion Fourth quarter and 2023 highlights Total fourth quarter revenue of $647 million, an increase of 17%, or 18% on a core revenue basis, with Screening revenue of $487 million and Precision Oncology revenue of $160 million Total 2023 revenue of $2.50 billion, an increase of 20%, or 24% on a core revenue basis, with Screening revenue of $1.865 billion and Precision Oncology revenue of $629 million Fourth quarter cash provided by operating activities was $70 million and free cash flow was $35 million Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and di

Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its fourth quarter 2023 financial results after the close of the U.S. financial markets on February 21, 2024. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. Fourth quarter 2023 webcast & conference call details Date: Wednesday, February 21, 2024 Time: 5 p.m. ET Webcast: The live webcast can be accessed at www.exactsciences.com Telephone: Domestic callers, dial 888-330-2384 International

MADISON, Wis., Oct. 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third quarter 2023 financial results after the close of the U.S. financial markets on November 1, 2023. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. Third quarter 2023 webcast & conference call details Date: Wednesday, November 1, 2023 Time: 5 p.m. ET Webcast: The live webcast can be a

Reports record results, generates positive free cash flow, raises full-year guidance Second-quarter 2023 highlights Total second quarter revenue of $622 million, an increase of 19%, and $617 million of core revenue, an increase of 24%Cash provided by operating activities was $100 million and free cash flow was $66 millionFull-year 2023 revenue and adjusted EBITDA guidance raised by $54 million and $63 million at the midpoints, respectivelyMADISON, Wis., Aug. 1, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $622.1 million for the second quarter ended June 30, 2023, com

MADISON, Wis., July 10, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2023 financial results after the close of the U.S. financial markets on August 1, 2023. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. Second quarter 2023 webcast & conference call details Date: Tuesday, August 1, 2023 Time: 5 p.m. ET Webcast: The live webcast can be acce

Reports record results, raises full-year guidance, accelerates path to positive free cash flow First quarter highlights Total first quarter revenue of $602 million, an increase of 24%, and $598 million of core revenue, an increase of 33%Full-year 2023 revenue guidance raised by $110 million at the midpointExpect to turn free cash flow positive during 2023, ahead of previous target of 2024MADISON, Wis., May 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $602.5 million for the first quarter ended March 31, 2023, compared to $486.6 million for the same period of 2022.

MADISON, Wis., April 10, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 2023 financial results after the close of the U.S. financial markets on May 9, 2023. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. First quarter 2023 webcast & conference call details Date:            Tuesday, May 9, 2023 Time:            5 p.m. ET Webcast:      The live

Reports record revenue, expects revenue of $2,265-2,315 million and positive adjusted EBITDA for full year 2023 Fourth quarter and 2022 highlights Total fourth quarter revenue of $553 million, an increase of 17% or 28% excluding COVID-19 testing, with Screening revenue of $404 million and Precision Oncology revenue of $143 millionTotal 2022 revenue of $2,084 million, an increase of 18% or 25% excluding COVID-19 testing, with Screening revenue of $1,425 million and Precision Oncology revenue of $601 millionSurpassed 12 million cumulative people tested for cancer, including 10 million with Cologuard®MADISON, Wis., Feb. 21, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ:EXAS), a leading prov

MADISON, Wis., Feb. 1, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its fourth quarter 2022 financial results after the close of the U.S. financial markets on February 21, 2023. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. Fourth quarter 2022 webcast & conference call details Date:            Tuesday, February 21, 2023 Time:              5 p.m. ET Webcast:

Reports Record Revenue, Raises Full-Year Guidance, Accelerates Path to Profitability Third quarter highlights Total third quarter revenue, excluding COVID-19 testing, increased 20 percent compared to the third quarter of 2021, with Screening revenue of $361 million and Precision Oncology revenue of $151 millionFull-year revenue guidance raised by $33 million and operating expense guidance lowered by $113 million at the midpointsAdjusted EBITDA profitability now expected in the third quarter of 2023, ahead of previous target of 2024MADISON, Wis., Nov. 3, 2022 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that t

MADISON, Wis., Oct. 10, 2022 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third quarter 2022 financial results after the close of the U.S. financial markets on November 3, 2022. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. Third quarter 2022 webcast & conference call details Date:          Thursday, November 3, 2022 Time:            5 p.m. ET Webcast:     

Second quarter highlights Total second quarter revenue of $522 million, including Screening revenue of $354 million, Precision Oncology revenue of $154 million, and COVID-19 testing revenue of $14 millionTotal second quarter revenue, excluding COVID-19 testing, increased 26 percent compared to the second quarter of 2021, including 34 percent increase in Screening revenue and 12 percent increase in Precision Oncology revenueScreening revenue growth driven by improved sales team productivity, Cologuard marketing partnership with Katie Couric, Cologuard rescreens, and Cologuard use in 45-49 age groupMADISON, Wis., Aug. 2, 2022 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ:EXAS), a leading provid

MADISON, Wis., July 8, 2022 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2022 financial results after the close of the U.S. financial markets on August 2, 2022. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. Second quarter 2022 webcast & conference call details Date:          Tuesday, August 2, 2022 Time:            5 p.m. ET Webcast: The live

Total first quarter revenue of $487M, including Screening revenue of $307M, Precision Oncology revenue of $153M, and COVID-19 testing revenue of $27MTotal first quarter revenue, excluding COVID-19 testing, increased 24% compared to the first quarter of 2021, including 28% increase in Screening revenue and 18% increase in Precision Oncology revenueScreening revenue growth driven by improved sales team productivity, Cologuard rescreens, and Cologuard use in 45-49 age groupMADISON, Wis., April 26, 2022 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ:EXAS), a leader in advanced cancer diagnostics, today announced that the company generated revenue of $486.6 million for the first quarter ended March

MADISON, Wis., April 8, 2022 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ:EXAS), a leader in advanced cancer diagnostics, today announced that the company plans to release its first quarter 2022 financial results after the close of the U.S. financial markets on April 26, 2022. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. First quarter 2022 webcast & conference call details Date:                        Tuesday, April 26, 2022 Time:                        5 p.m. ET Webcast:     

MADISON, Wis., Feb. 22, 2022 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ:EXAS), a leader in advanced cancer diagnostics, today announced that the company generated revenue of $473.8 million for the fourth quarter ended Dec. 31, 2021 and $1,767.1 million for the full year ended Dec. 31, 2021. "Cologuard® and Oncotype DX® are off to a great start in 2022, with strong momentum from the fourth quarter carrying over to the new year," said Kevin Conroy, chairman and CEO of Exact Sciences. "We have a team of talented people dedicated to defeating cancer. You'll see the results of th

MADISON, Wis., Feb. 8, 2022 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ:EXAS), a leader in advanced cancer diagnostics, today announced that the company plans to release its fourth quarter 2021 financial results after the close of the U.S. financial markets on February 22, 2022. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. Fourth quarter 2021 webcast & conference call details                 Date:                  Tuesday, February 22, 2022                 Time:              

MADISON, Wis., Jan. 18, 2022 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ:EXAS) today announced performance data for a second-generation Cologuard (multi-target stool DNA) test showing overall sensitivity of 95.2% for colorectal cancer (CRC) at specificity of 92.4% for negative samples confirmed by colonoscopy. Subgroup analyses showed 83.3% sensitivity for high-grade dysplasia, the most dangerous precancerous lesions, and 57.2% for all advanced precancerous lesions. These data will be presented January 22 at ASCO GI in a poster titled, "Second-generation Multi-target Stool DNA Panel Reliably Detects Colorectal Cancer and Advanced Precancerous Lesions." Cologuard is the first and only FDA-ap

MADISON, Wis., Nov. 2, 2021 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ:EXAS) today announced that the company generated revenue of $456.4 million for the third quarter ended September 30, 2021, compared to $408.4 million for the same period of 2020. "Exact Sciences is entering an exciting period for its pipeline, generating evidence to support innovative tests that will help defeat cancer through earlier detection," said Kevin Conroy, chairman and CEO. "Our powerful commercial engine will help us achieve our mission by getting more people tested with Cologuard®, Oncotype DX®

MADISON, Wis., Oct. 8, 2021 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ:EXAS) today announced that the company plans to release its third quarter 2021 financial results after the close of the U.S. financial markets on November 2, 2021. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. Third quarter 2021 webcast & conference call details Date:                        Tuesday, November 2, 2021Time:                        5 p.m. ETWebcast:                  The live webcast can be acce

MADISON, Wis., July 28, 2021 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ:EXAS) today announced that the company generated revenue of $434.8 million for the second quarter ended June 30, 2021, compared to $268.9 million for the same period of 2020. "The Exact Sciences team remained unwavering in their dedication to our mission and delivered record results for Cologuard® and Oncotype DX®," said Kevin Conroy, chairman and CEO. "We have a strong foundation in cancer screening and precision oncology and plan to transform cancer care with Cologuard, Oncotype, and our deep pipeline